ATE412650T1 - Isethionat salz eines selektiven cdk4 inhibitors - Google Patents

Isethionat salz eines selektiven cdk4 inhibitors

Info

Publication number
ATE412650T1
ATE412650T1 AT04737186T AT04737186T ATE412650T1 AT E412650 T1 ATE412650 T1 AT E412650T1 AT 04737186 T AT04737186 T AT 04737186T AT 04737186 T AT04737186 T AT 04737186T AT E412650 T1 ATE412650 T1 AT E412650T1
Authority
AT
Austria
Prior art keywords
cdk4 inhibitor
selective cdk4
isethionate salt
isethionate
salt
Prior art date
Application number
AT04737186T
Other languages
English (en)
Inventor
Vladimir Genukh Beylin
Anthony Clyde Blackburn
David Erdman
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE412650T1 publication Critical patent/ATE412650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04737186T 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors ATE412650T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
ATE412650T1 true ATE412650T1 (de) 2008-11-15

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04737186T ATE412650T1 (de) 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors

Country Status (31)

Country Link
US (2) US7345171B2 (de)
EP (1) EP1648889B1 (de)
JP (1) JP4053073B2 (de)
KR (1) KR100816945B1 (de)
CN (1) CN1835951B (de)
AR (1) AR045898A1 (de)
AT (1) ATE412650T1 (de)
AU (1) AU2004255934B2 (de)
BR (1) BRPI0412516A (de)
CA (1) CA2532049C (de)
CL (1) CL2004001701A1 (de)
CY (1) CY1108589T1 (de)
DE (1) DE602004017474D1 (de)
DK (1) DK1648889T3 (de)
ES (1) ES2313016T3 (de)
GT (1) GT200400130A (de)
IL (1) IL173034A (de)
MX (1) MXPA06000484A (de)
NL (1) NL1026624C2 (de)
NO (1) NO335100B1 (de)
NZ (1) NZ544609A (de)
PA (1) PA8606501A1 (de)
PE (1) PE20050700A1 (de)
PL (1) PL1648889T3 (de)
PT (1) PT1648889E (de)
RU (1) RU2317296C2 (de)
SI (1) SI1648889T1 (de)
TW (1) TWI288750B (de)
UY (1) UY28404A1 (de)
WO (1) WO2005005426A1 (de)
ZA (1) ZA200600230B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP46108A (en) 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
WO2008032157A2 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
DK2074122T5 (da) 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010513317A (ja) * 2006-12-14 2010-04-30 パナシー ファーマシューティカルズ インコーポレーティッド サイクリン依存性キナーゼの阻害による神経保護方法
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5530422B2 (ja) * 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
CA2738925A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
WO2010051127A2 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
MX349923B (es) 2009-04-03 2017-08-21 Hoffmann La Roche Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas.
WO2010132725A2 (en) 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CN103501789A (zh) * 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012173694A1 (en) 2011-06-17 2012-12-20 Fluidic, Inc. Ionic liquid containing sulfonate ions
EP3216792B1 (de) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactamkinaseinhibitoren
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3431475B1 (de) * 2013-02-21 2021-04-07 Pfizer Inc Feste formen eines selektiven cdk4/6 inhibitors
WO2014144847A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014150925A2 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
WO2016016769A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
EP3180007A1 (de) * 2014-08-14 2017-06-21 Sun Pharmaceutical Industries Ltd Kristalline formen von palbociclib
EP3191098A4 (de) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
HUE061672T2 (hu) 2014-11-12 2023-08-28 Seagen Inc Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
EP3255046B1 (de) * 2015-02-03 2019-11-27 Jiangsu Hengrui Medicine Co., Ltd. Hydroxyethylsulfonat des cyclinabhängigen proteinkinaseinhibitors, kristalline form davon und herstellungsverfahren davon
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (de) 2015-04-09 2016-10-12 Sandoz Ag Modifizierte partikel von palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
AR104789A1 (es) * 2015-05-29 2017-08-16 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
RS59672B1 (sr) * 2015-06-04 2020-01-31 Pfizer Čvrsti dozni oblici palbocikliba
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
EP3331881B1 (de) 2015-08-05 2019-05-15 ratiopharm GmbH Neue kristalline form und essigsäureaddukte von palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) * 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
WO2017172734A1 (en) * 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Treating cancer metastasis
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
US10597393B2 (en) 2016-07-07 2020-03-24 Plantex Ltd. Solid state forms of Palbociclib dimesylate
SI3497103T1 (sl) 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
MA45887B1 (fr) * 2016-11-28 2021-04-30 Teijin Pharma Ltd Cristal de dérivé de pyrido [3, 4-d] pyrimidine ou son solvate
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
MA47812A (fr) 2017-03-03 2021-04-14 Seagen Inc Composés interagissant avec le glycane et méthodes d'utilisation
CN110573183A (zh) * 2017-04-21 2019-12-13 上海方楠生物科技有限公司 一种帕博西林组合物及其制备方法
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
US11529353B2 (en) 2017-07-28 2022-12-20 Synthon B.V. Pharmaceutical composition comprising Palbociclib
US11352341B2 (en) * 2018-01-29 2022-06-07 Beta Pharma, Inc. 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
US20200405809A1 (en) 2018-02-27 2020-12-31 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
WO2019220253A1 (en) 2018-05-14 2019-11-21 Pfizer Inc. Oral solution formulation
EP3826622A1 (de) 2018-07-23 2021-06-02 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs mit pi3k-inhibitor, gdc-0077
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
WO2020076432A1 (en) 2018-10-08 2020-04-16 Genentech, Inc. Methods of treating cancer with pi3k alpha inhibitors and metformin
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
EP3976043A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
IL290789B2 (en) 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
JP2023504436A (ja) 2019-12-03 2023-02-03 ジェネンテック， インコーポレイテッド 乳がんの治療のための併用療法
WO2021176349A1 (en) 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4181920B1 (de) 2020-07-15 2025-09-10 Pfizer Inc. Kat6-inhibitor und kombinationen zur brustkrebsbehandlung
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
CN114246841B (zh) * 2020-09-24 2024-02-02 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
CA3240454A1 (en) 2021-12-10 2023-06-15 Lacey Morgan LITCHFIELD Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302755B1 (de) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Eine aminosäure enthaltende palbociclib-formulierung
EP4302832A1 (de) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib-formulierung, die glucono-delta-lacton enthält
CA3263126A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. DOSING REGIMEN INCLUDING A KAT6 INHIBITOR FOR CANCER TREATMENT
TW202539669A (zh) 2022-08-31 2025-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
AU2023373671A1 (en) 2022-11-02 2025-05-15 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
TW202532065A (zh) 2023-12-04 2025-08-16 美商建南德克公司 治療乳癌之組合療法
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT790997E (pt) * 1994-11-14 2000-06-30 Warner Lambert Co 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica
EP1268476A1 (de) * 2000-03-06 2003-01-02 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidin tyrosine kinase inhibitoren
US6720332B2 (en) * 2000-09-01 2004-04-13 Smithkline Beecham Corporation Oxindole derivatives
ATE323706T1 (de) * 2001-12-17 2006-05-15 Smithkline Beecham Corp Pyrazolopyridazinderivate
MEP46108A (en) * 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
AU2003287178A1 (en) * 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
ES2315566T3 (es) * 2002-11-22 2009-04-01 Smithkline Beecham Corporation Tiazolidin-4-onas para inhibir proteinas hyak3.
EP1590341B1 (de) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
ES2312968T3 (es) * 2003-02-27 2009-03-01 Smithkline Beecham Corporation Compuestos novedosos.

Also Published As

Publication number Publication date
GT200400130A (es) 2005-07-14
HK1091205A1 (zh) 2007-01-12
CY1108589T1 (el) 2014-04-09
NO20060386L (no) 2006-04-05
SI1648889T1 (sl) 2009-02-28
RU2317296C2 (ru) 2008-02-20
JP4053073B2 (ja) 2008-02-27
US20080021037A1 (en) 2008-01-24
AR045898A1 (es) 2005-11-16
PL1648889T3 (pl) 2009-03-31
EP1648889A1 (de) 2006-04-26
RU2006101052A (ru) 2006-07-27
JP2007530425A (ja) 2007-11-01
CA2532049C (en) 2010-07-20
EP1648889B1 (de) 2008-10-29
IL173034A (en) 2010-06-16
KR20060054300A (ko) 2006-05-22
US20050059670A1 (en) 2005-03-17
NL1026624C2 (nl) 2005-07-20
NZ544609A (en) 2008-07-31
WO2005005426A1 (en) 2005-01-20
PA8606501A1 (es) 2005-03-03
DE602004017474D1 (de) 2008-12-11
BRPI0412516A (pt) 2006-09-19
CA2532049A1 (en) 2005-01-20
TWI288750B (en) 2007-10-21
MXPA06000484A (es) 2006-04-05
US7863278B2 (en) 2011-01-04
TW200516079A (en) 2005-05-16
NO335100B1 (no) 2014-09-15
CN1835951B (zh) 2010-06-02
US7345171B2 (en) 2008-03-18
DK1648889T3 (da) 2009-01-05
ZA200600230B (en) 2007-04-25
KR100816945B1 (ko) 2008-03-25
NL1026624A1 (nl) 2005-01-12
UY28404A1 (es) 2005-02-28
PT1648889E (pt) 2008-12-10
AU2004255934B2 (en) 2010-02-25
CN1835951A (zh) 2006-09-20
CL2004001701A1 (es) 2005-06-03
PE20050700A1 (es) 2005-10-18
AU2004255934A1 (en) 2005-01-20
ES2313016T3 (es) 2009-03-01
IL173034A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
ATE412650T1 (de) Isethionat salz eines selektiven cdk4 inhibitors
ATE373003T1 (de) Phosphorsäuresalz eines dipeptidylpeptidase-iv- inhibitors
ATE534645T1 (de) Kaliumsalz eines hiv-integrasehemmers
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
IS7483A (is) Bensamíðafleiður gagnlegar sem históndeasetýlasatálmar
EP1945617A4 (de) Histondeacetylaseinhibitoren mit arylpyrazolylmotiven
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
ATE425152T1 (de) Aminocarbonylderivate als histone-deacetylase- inhibitoren
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
ATE395343T1 (de) Sulfonylderivate als histone-deacetylase- inhibitoren
ITVA20050027A1 (it) Metodo di generazione di successioni di numeri o bit pseudo casuali
DK1699455T3 (da) Heterocykliske aspartylproteasehæmmere
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
EP1789381A4 (de) Histondeacetylase-hemmer
DK1912949T3 (da) Cyclohexylaminisoquinolon-derivater som inhibitorer af rho-kinase
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
NO20051236L (no) Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
EP1660436A4 (de) Cathepsininhibitoren
ATE440821T1 (de) Isochinolinderivate als mao-b inhibitoren
EP1613311A4 (de) Hif-1-hemmer
NO20044806L (no) N-acylaminobenzen-derivater som selektive monoamin-oksidase B inhibitorer
DE50311093D1 (de) Lagefixierung eines bolzens
IS8201A (is) Nikótínamíð afleiður gagnlegar sem PDE4 hindrar

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648889

Country of ref document: EP